Intas Pharmaceuticals To Market Bortezomib In India – Intas Biopharmaceuticals has recently launched Borviz (bortezomib) in India for the treatment of multiple myeloma. Bortezomib is marketed in the U.S. under the brand name Velcade. The medication is given as an intravenous injection, and the dosage is based on individual medical conditions. About 3.5 million cancer cases have been diagnosed in India and statistics show that the age of onset for multiple myeloma is decreasing from the current 65 years of age. For more information about Borviz see the India PR Wire press release.

Myeloma: Understanding Drug Therapy And Stem Cell Transplantation – The Leukemia & Lymphoma Society (LLS) is sponsoring this free teleconference on May 14 from noon to 1:30 p.m. EST. Dr. Seema Singhal, Professor of Medicine and Director of the Myeloma Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, will present on the topic and take questions from participants. For more information, please visit the LLS Web site.

Honolulu Triathlon – On May 17, members of the Leukemia & Lymphoma Society’s (LLS) Team In Training program will participate in this Hawaiian triathlon. There will be both international and sprint races. For more information, please visit the LLS Web site.